Neurodegenerative disease research
9 European H2020 organizations list this as part of their work — 6 as their primary capability.
Most active in this area
- ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Leading Dutch university medical center specializing in personalised medicine, life-course epidemiology, and FAIR health data infrastructure across 173 H2020 projects.
“CoSTREAM (coordinated, EUR 1.1M) linked stroke and Alzheimer's mechanisms; the Dementia project and EuroPOND modeled neurological disease progression.”
NL173 projects - NOVARTIS PHARMA AG
Global pharmaceutical company contributing clinical data, drug safety expertise, and translational medicine capabilities to large-scale European health research consortia.
“Participation in IMPRiND (protein misfolding in neurodegeneration), ROADMAP (Alzheimer's real-world evidence), IM2PACT (blood-brain-barrier delivery), and related projects.”
CH57 projects - TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Global pharma company contributing CNS therapeutics expertise, clinical datasets, and pharmacovigilance to large European health research consortia.
“Consistent involvement across PD-MitoQUANT (Parkinson's mitochondrial dysfunction), AIMS-2-TRIALS (autism/neurodevelopment), EPND (Alzheimer's/Parkinson's biomarkers), and MOBILISE-D (digital mobility in PD).”
PrimaryIL11 projects - INSTITUT DE RECHERCHES SERVIER
French pharmaceutical research institute contributing drug discovery, screening platforms, and disease models to European oncology and neurodegeneration consortia.
“Participated in IMPRiND targeting protein aggregation/propagation and EBiSC2 with neurodegeneration-specific iPSC lines.”
PrimaryFR9 projects - UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN
Major German university hospital active in Parkinson's research, precision cancer diagnostics via liquid biopsy, and digital health endpoints.
“Three projects target neurodegeneration: FAIR-PARK-II (Parkinson's iron chelation trial), SysMedPD (mitochondrial Parkinson's), and IDEA-FAST (digital endpoints for neurodegenerative and inflammatory disorders).”
PrimaryDE8 projects - HELSE STAVANGER HF
Norwegian university hospital contributing clinical data, patient cohorts, and digital health expertise to European chronic disease and AI pathology research.
“PD-MIND investigates nicotinic agonist treatment for Parkinson's disease with mild cognitive impairment, using biomarker and imaging endpoints.”
NO7 projects - AZIENDA UNITA' SANITARIA LOCALE DI BOLOGNA
Bologna clinical research institute contributing neuroscience expertise, patient cohorts, and healthcare system data to European health and AI projects.
“PROPAG-AGEING focused on Parkinson's Disease propagation mechanisms; MAIA develops brain-derived prosthetic control for brain-injured patients.”
PrimaryIT6 projects - YEREVAN STATE MEDICAL UNIVERSITY AFTER MKHITAR HERATSI
Armenian medical university building European-level research infrastructure in neuroscience, cancer genetics, and clinical diagnostics.
“COBRAIN established a translational research center on chronic neurodegenerative disorders, coordinated by YSMU with EUR 374,919 in funding.”
PrimaryAM3 projects - CENTRO DE INVESTIGACION BIOMEDICA EN RED ENFERMEDADES NEURODEGENERATIVAS
Spanish national research network specializing in Alzheimer's biomarkers, neuroinflammation, and neurodegenerative disease mechanisms.
“Both BBDiag and PurinesDX directly target neurodegeneration — Alzheimer's diagnostics and neuroinflammatory mechanisms respectively.”
PrimaryES2 projects